Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr11.60 DKK
Change Today -0.20 / -1.69%
Volume 9.9K
EXQ On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
As of 4:59 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Open
kr12.00
Previous Close
kr11.80
Day High
kr12.00
Day Low
kr11.60
52 Week High
06/3/15 - kr15.40
52 Week Low
10/3/14 - kr4.40
Market Cap
427.7M
Average Volume 10 Days
128.0K
EPS TTM
kr-0.06
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXIQON A/S (EXQ)

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides life science research products worldwide. It operates through two segments, Life Sciences and Diagnostics. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include miRCURY RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive, and detection of microRNAs by Northern blot analysis and in situ hybridization; and microRNA inhibitor and target site blockers for functional analysis. It also offers microarrays capture probes for expression analysis of splice variants, small RNAs, and mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; and longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function. In addition, the company provides oligonucleotides and microarray capture probes to detect single nucleotide polymorphism; FISH probes to detect chromosomal DNA sequences; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher for real-time PCR probes. Further, it offers RNA isolation services for the sample types, including exosome isolation, blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array and profiling services; microRNA and Small RNA sequencing services; microRNA in situ hybridization screening services; and custom pharma services, such as biomarker discovery, validation experiments, and others. The company markets its research products through direct sales, distributors, and the Web. Exiqon A/S was founded in 1995 and is headquartered in Vedbæk, Denmark.

91 Employees
Last Reported Date: 08/25/15
Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr3.3M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: kr2.2M
Compensation as of Fiscal Year 2014.

exiqon a/s (EXQ) Key Developments

Exiqon A/S Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for Full Year 2015

Exiqon A/S announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of DKK 38,016,000 against DKK 30,722,000 a year ago. Operating profit was DKK 822,000 against operating loss of DKK 1,527,000 a year ago. Profit for the period was DKK 15,000 against loss of DKK 1,243,000 a year ago. Loss before tax was DKK 0.122 million against DKK 2.164 million a year ago. EBITDA was DKK 2.6 million against DKK 0.1 million a year ago. Cash flows from operating activities was DKK 3.4 million against DKK 1.3 million a year ago. For the six months, the company reported revenue of DKK 77,038,000 against DKK 63,193,000 a year ago. Operating profit was DKK 1,771,000 against operating loss of DKK 1,056,000 a year ago. Profit for the period was DKK 44,000 against loss of DKK 450,000 a year ago. Loss before tax was DKK 0.370 million against DKK 2.240 million a year ago. Cash flows from operating activities were DKK 4,655,000 against cash flows used in operating activities of DKK 965,000 a year ago. Acquisition of property, plant and equipment was DKK 427,000 against DKK 1,823,000 a year ago. Acquisition of intangible assets was DKK 2,033,000 against DKK 1,417,000 a year ago. EBITDA was DKK 5.2 million against DKK 1.7 million a year ago. The company raises its full year guidance to revenues of DKK 155-160 million, previously DKK 150-160 million and EBITDA around DKK 10 million, previously DKK 5-10 million based on an average USD/DKK exchange rate of DKK 6.50.

Exiqon A/S Launches XploreRNATM Cloud-Computing Environment

Exiqon A/S announced the launch of its XploreRNATM cloud-computing environment. XploreRNATM brings together for the first time applications for RNAseq data analysis with custom assay design capabilities in one integrated work-flow that is supported by a full-fledged e-commerce system, allowing customers to quickly and easily purchase assays to their individual specifications. XploreRNATM enables the entire RNAseq workflow in three user-friendly steps that can be completed without any knowledge of bioinformatics: Step 1: RNAseq data analysis: RNAseq data including Illumina Inc. and Thermo Fisher Scientific Inc., may be submitted for analysis to the XploreRNATM cloud-computing environment, hosted by Amazon to ensure fast data upload throughout the world. Results from the RNA sequencing data analyses are separately available to customers in the form of a highly advanced report. The report is designed to become interactive and allow for advanced search opportunities to identify interesting microRNAs, mRNAs and lncRNAs (long non-coding RNAs). Major databases including Ensembl, miRBase etc. have been cross-annotated to provide for all-in-one searches. Relevant abstracts and original publications are integrated through PubMed to enrich search results. XploreRNATM does not depend on customer's having their sequencing performed by Exiqon Services, however, RNA sequencing customers will benefit from additional integration of the data analysis and flexible product solutions offered by Exiqon; Step 2: RNAseq data sorting: RNAseq results are summarized in simple and readily understandable tables and diagrams. A unique Gene Sorting WizardTM enables user-friendly sorting of results, according to desired parameters, e.g. differential expression, and effortless identification of genes or transcripts of interest; and Step 3: RNA analysis with customized assay design capability: Upon sorting of the RNAseq data, a series of applications allow customers to automatically design assays according to their own specifications, whether for RNA validation or RNA functional analysis. Products are automatically customized by advanced proprietary bioinformatics algorithms developed by Exiqon to secure optimal design in combination with the LNATM technology. Eventually products for all kinds of analyses will be available in XploreRNATM. The custom designed products are readily available for purchase through a fully integrated web shop. Exiqon also launches a new and advanced qPCR product portfolio, ExiLERATE, for real-time PCR detection of mRNA and lncRNA to complement the company's miRCURY LNATM Universal RT microRNA PCR system.

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for 2015

Exiqon A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of DKK 39,022,000 against DKK 32,471,000 a year ago. Operating profit was DKK 949,000 against operating loss of DKK 471,000 a year ago. Profit for the period was DKK 23,000 or DKK 0.00 per diluted share against DKK 793,000 or DKK 0.02 per diluted share a year ago. Cash flows from operating activities were DKK 1,213,000 against cash flows used in operating activities of DKK 2,312,000 a year ago. Acquisition of property, plant and equipment was DKK 246,000 against DKK 480,000 a year ago. Loss before tax was DKK 76 million against DKK 248 million a year ago. EBITDA was DKK 2.7 million against DKK 1.6 million a year ago. Acquisition of intangible assets was DKK 333,000 against DKK 502,000 a year ago. The company reiterates its full year guidance of revenues between DKK 150-160 million and EBITDA of DKK 5-10 million based on an average USD/DKK exchange rate of DKK 6.50.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXQ:DC kr11.60 DKK -0.20

EXQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $12.19 USD +0.49
Foundation Medicine Inc $23.54 USD -0.26
HTG Molecular Diagnostics Inc $5.57 USD -0.1199
NanoString Technologies Inc $15.21 USD -0.05
WaferGen Bio-systems Inc $1.20 USD +0.03
View Industry Companies
 

Industry Analysis

EXQ

Industry Average

Valuation EXQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXIQON A/S, please visit www.exiqon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.